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COMMENTARY
TO THE EDITOR:
CD19 antibody-drug conjugate therapy in DLBCL does not preclude
subsequent responses to CD19-directed CAR T-cell therapy
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Northside Hospital, Atlanta, GA; 5Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico,
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Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin
lymphoma (NHL), with aggressive clinical behavior.1 Approximately 40% to 50% of DLBCL patients are
refractory to or relapse after frontline chemoimmunotherapies.2 Management of relapsed/refractory DLBCL
is challenging, and treatment options include salvage therapy followed by autologous hematopoietic cell
transplantation (autoHCT), in younger, chemosensitive patients.3 CD19-directed chimeric antigen receptor
(CAR) modified T-cell therapy is another potentially curative option for patients with relapse after autologous
hematopoietic cell transplantation or those with refractory disease.4 Axicabtagene ciloleucel and
tisagenlecleucel are 2 anti-CD19 CAR T-cell treatments approved by the US Food and Drug Administration
for relapsed/refractory DLBCL.5,6
The CD19 antigen is an attractive target for immunotherapy in B-cell non-Hodgkin lymphoma. It is expressed
during B-cell development only after B-lineage commitment and is thus not present on hematopoietic stem
cells.7 CD19 expression is lost during terminal plasma cell differentiation but maintained in hematologic B-cell
malignancies.7 Several clinical trials using monoclonal antibodies,8 antibody-drug conjugates (ADCs),9 and
bispecific T-cell engagers targeting the CD19 antigen are ongoing in B-cell non-Hodgkin lymphoma. Studies
investigating CD19-directed CAR T-cell therapies in aggressive lymphomas frequently excluded patients
previously treated with CD19 targeting immunotherapies. Hence, the feasibility and efficacy of anti-CD19
CARs in lymphoma patients with prior CD19-directed immunotherapies are not known. Loncastuximab
tesirine is an ADC comprising a humanized anti-CD19 monoclonal antibody stochastically conjugated to
a pyrrolobenzodiazepine dimer toxin, SG3199.10 A phase 1 first-in-human study of loncastuximab tesirine
demonstrated encouraging clinical activity in patients with relapsed/refractory DLBCL,9 and a phase 2 study
recently finished patient accrual (#NCT03589469).
We sought to evaluate the outcomes of anti-CD19 CAR T-cell therapy in relapsed, refractory DLBCL
previously treated with CD19-directed immunotherapy. Adult (age $18 years) DLBCL patients were
identified from 2 multicenter, open-label studies of loncastuximab tesirine (phase 1: #NCT02669017
and phase 2: #NCT03589469), who subsequently received anti-CD19 CAR T-cell therapy. This
retrospective analysis was approved by the institutional review board. Deidentified patient data were
collected in collaboration with 6 academic medical centers (US centers 5 4; United Kingdom5 1; Italy
5 1) involved in the loncastuximab tesirine trials. Cytokine release syndrome was graded using Lee et al
2014 criteria,11 and neurotoxicity was graded as per Common Terminology Criteria for Adverse Events,
version 5.0.
A total of 14 DLBCL patients with disease relapsing or progressing after treatment with loncastuximab
tesirine and subsequently undergoing CD19-directed CAR T-cell therapy were identified (Table 1).
Among the 14 patients, 11 patients (79%) were male, and 13 patients (93%) were white. The median
age was 58.5 years (range, 27 to 86). Ten had de novo DLBCL (germinal center B-cell–like 5 4;
non–germinal center B-cell5 2; not known5 4), and 4 patients had DLBCL transforming from indolent
histologies (marginal zone lymphoma 5 1; follicular lymphoma 5 1; nodular lymphocyte predominant
Hodgkin lymphoma 5 1). Five patients (36%) had a high-intermediate international prognostic index at
the time of diagnosis. c-MYC gene rearrangement was identified in 3 patients (21%) (1 patient had
triple-hit lymphoma), whereas c-MYC status was unknown in 3 patients (21%). The median interval
between diagnosis of DLBCL and initiation of loncastuximab tesirine was 21.5 months (range, 6.8
to 258). These patients received a median of 2 cycles (range, 1 to 7) of loncastuximab tesirine.
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The antitumor response to loncastuximab tesirine in these 14 patients
was as follows: 8 patients (57%) had refractory disease, 5 patients
(36%) attained partial response, and 1 patient (7%) achieved
a complete response (overall response rate [ORR] 5 43%). All
responding patients had progression of the disease before pro-
ceeding with CAR therapy.
Table 2 summarizes details of CAR T-cell therapy in these subjects.
The median interval between loncastuximab tesirine and CAR T-cell
therapy was 120 days (range, 22 to 600). Six patients received
additional lines of therapy between loncastuximab tesirine and CAR
T-cell treatment (median of 1 therapy line; range, 1 to 3). The CD19
expression was assessed by immunohistochemical staining on
repeat biopsies in 10 patients (71%) in between loncastuximab
tesirine and CAR administration. All 10 tested patients were positive
for CD19 after ADC failure. This information was not available in
4 patients (29%). Before CAR T-cell administration, 13 patients had
refractory or progressive disease, whereas 1 patient was in partial
remission. All patients received standard lymphodepletion with
fludarabine and cyclophosphamide before CAR T-cell therapy. The
type of anti-CD19 CAR T-cell therapy received by the patients
included axicabtagene ciloleucel (n 5 5), tisagenlecleucel (n 5 2),
JCAR017 (n5 3), and investigational CARs targeting CD19 (n5 4;
including 2 patients with CARs targeting dual antigens; Table 2).
The median follow-up of survivors was 6 months (range, 3 to 22).
Grade 1 to 2 cytokine release syndrome was common (n5 7; 50%).
Grade 1 immune effector cell–associated neurotoxicity syndrome
(ICANS) was identified in 4 patients (29%), and only 1 patient had
grade 4 ICANS. Following CAR therapy, the best response at
3 months included 6 patients (43%) with a complete response and
1 patient (7%) with a partial response (ORR 5 50%). Seven patients
had refractory disease following CAR therapy. Five of 6 complete
Table 1. Patient demographics and disease characteristics
Patients (N 5 14)
Age, median (range), y 58.5 (27-86)
Sex, n (%)
Male 11 (79)
Female 3 (21)
Race, n (%)
White 13 (93)
African American/black 1 (7)
Lymphoma subtype
DLBCL* 10
Transformed DLBCL 4
IPI at diagnosis, n (%)
Low (0, 1) 3 (21)
Low-intermediate (2) 3 (21)
High-intermediate (3) 5 (36)
Unknown 3 (21)
Advanced stage (III/IV) at diagnosis 4 (29)
c-MYC rearrangement, n (%)
Yes 3 (21)
No 8 (57)
Unknown 3 (21)
Median interval between diagnosis and start of
loncastuximab tesirine (range), mo
21.5 (6.8-258)
Best response to loncastuximab tesirine, n (%)
Complete response 1 (7)
Partial response 5 (36)
Percentages may not add up to 100 due to rounding.
IPI, International Prognostic Index.
*One patient had mediastinal large B-cell lymphoma.
Table 2. CAR T-cell therapy in DLBCL patients failing CD19-directed
treatment
Patients (N 5 14)
CD19 expression on lymphoma cells after loncastuximab
tesirine therapy, n (%)
Positive 10 (71)
Not checked 4 (29)
Median interval between loncastuximab tesirine and CAR T-cell
therapy (range), d
120 (22-600)
Additional therapy between loncastuximab tesirine and
CAR T-cell therapy, n (%)
Yes* 6 (43)
No 8 (57)
Disease status before CAR T-cell therapy, n (%)
Refractory disease 5 (36)
Progressive disease 8 (57)
Partial remission 1 (7)
Flu/Cy lymphodepletion, n (%) 14 (100)
Type of CAR T-cell therapy, n (%)
Axicabtagene ciloleucel 5 (36)
Tisagenlecleucel 2 (14)
Investigational targeting CD19† 4 (29)
JCAR017 3 (21)
Best response to CAR T-cell therapy, n (%)
Complete response 6 (43)
Partial response 1 (7)
Refractory disease 7 (50)
CRS grade, n (%)
None 6 (43)
1 3 (21)
2 4 (29)
3 1 (7)
ICANS grade, n (%)
None 8 (57)
1 4 (29)
2 1 (7)
3 0 (0)
4 1 (7)
CRS, cytokine release syndrome; Flu/Cy, lymphodepletion with fludarabine/
cyclophosphamide.
*Additional therapy between loncastuximab tesirine and CAR T-cell therapy included
radiation alone (n 5 3), radiation, ifosphamide/vinblastine/etoposide (n 5 1), radiation;
rituximab/methotrexate (n 5 1), lenalidomide, anti-CD47 antibody, ibrutinib (n 5 1).
†One patient each received a CD19/CD22-directed CAR, and a CD19/CD20-directed
CAR. Neither patient responded to CAR treatment.
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remissions are ongoing at a median of 6 months (range, 6 to 11). One
patient with complete remission relapsed after 11 months and was
alive at last follow-up (122 months), whereas the patient achieving
a partial remission subsequently died because of progressive
lymphoma. Six out the 7 patients not achieving a CR expired at
a median of 5 months (range, 1 to 9) after CAR therapy. None of the
2 patients receiving dual-antigen targeting CARs (targeting CD19/
CD22 and CD19/CD20) achieved a response. All 4 patients with
unknown CD19 expression status after loncastuximab tesirine achieved
a complete remission with anti-CD19 CAR T-cell therapy, making it
unlikely that these patients had relapsed with a CD19-negative disease.
This is the first report, to our knowledge, evaluating the efficacy of
anti-CD19 CAR T-cell therapy after anti-CD19 immunotherapy. In
this series of 14 cases, favorable outcomes of CAR T-cell therapy
(ORR 5 50%) were seen in patients with relapsed/refractory
DLBCL after anti-CD19–targeted treatment with a pyrrolobenzo-
diazepine dimer–based ADCs. The toxicity profile of CAR treatment
in these subjects appears consistent with published data.5,6 CD19
expression on DLBCL was reassessed in 10 patients after relapse
or progression on loncastuximab tesirine treatment; no cases of
CD19 antigen-negative relapse were seen. We wish to acknowledge
that this report is limited by small sample size and retrospective
design. In conclusion, our report suggests that prior treatment with
anti-CD19 ADCs in relapsed/refractory DLBCL does not preclude
subsequent responses to anti-CD19CAR T-cell therapies. Additional
data on the feasibility of CAR therapy in patients receiving CD19
monoclonal antibodies and bispecific T-cell engagers are needed.
Send data sharing requests to the corresponding author, Mehdi
Hamadani (mhamadani@mcw.edu).
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